Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.
Overview
GLP-1 weight-loss drugs burst onto the scene when Novo Nordisk (NYSE: NVO) introduced Wegovy to the world. There was so much demand that the drug maker couldn't keep up. That shows the opportunity that this new class of weight-loss drugs offers, but it also explains why Novo Nordisk, while first to market, isn't the industry leader today. That title goes to Eli Lilly (NYSE: LLY).
After a massive decline of over 66% from its 2024 high, traditional valuation metrics suggest Novo Nordisk's stock is cheap. However, the bigger question you need to consider is the pharmaceutical company's ability to compete against Eli Lilly's now-dominant GLP-1 drugs. Here's a quick look at what you need to know about Novo Nordisk before you buy it.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.